Abstract
Ramucirumab (RAM) plus FOLFIRI has been considered as 2nd-line treatment standard of care for RAS wild-type metastatic colorectal cancer (mCRC) after anti-EGFR antibody containing chemotherapy. However, there have been few studies which prospectively evaluated the efficacy and safety of RAM plus FOLFIRI after anti-EGFR antibody therapy in mCRC. We therefore investigated the efficacy and safety of RAM plus FOLFIRI as 2nd-line treatment in patients with RAS wild-type mCRC previously treated with anti-EGFR antibody containing chemotherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
